Rolf Kiessling

13PUBLICATIONS
63CO-AUTHORS
Innate immunityTumour immunologyMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jul 09, 2026
BET inhibition synergizes with RLR signaling to enhance tumor immunogenicity and T cell recognition.

|Apr 30, 2026
Pleiotropic effects of BET inhibition broadly boost tumor immunogenicity to CD8+ T cells.

|Dec 07, 2024
Reactive oxygen species: Janus-faced molecules in the era of modern cancer therapy.

Aine O'Reilly, Wenchao Zhao, Stina Wickström

|May 15, 2024
Tumor-associated NK cells drive MDSC-mediated tumor immune tolerance through the IL-6/STAT3 axis.

Shi Yong Neo, Le Tong, Joni Chong

|Jun 23, 2022
Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress.

Stefanie Renken, Takahiro Nakajima, Isabelle Magalhaes

|Jul 09, 2021
Cisplatin inhibits frequency and suppressive activity of monocytic myeloid-derived suppressor cells in cancer patients.

Glenn F Van Wigcheren, Nienke De Haas, Tom A Mulder

Pageof 3

Frequent Collaborators

9 joint publications

Stina Wickström

5 joint publications

Andreas Lundqvist

3 joint publications

Tanja Lövgren

3 joint publications

Giuseppe Masucci